Home Services

Explore Our Main Services

We are a company specialized in developing the following services:

Multiple Myeloma (MM)

Is a bone marrow plasma cell dysplasia that represents 2% of all new cancer cases and over 17% of hematologic malignancies.

Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) represents 1.2% of all new cancer cases and is the most common type of acute leukemia in adults

Acute Lymphoblastic Leukemia (ALL)

Represents 3% of hematologic neoplasias and is a heterogeneous disease characterized by the proliferation of immature lymphoid cells in bone marrow, peripheral blood, and other organs.

Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is a type of leukemia with small, mature lymphocytes which represents 1.4% of all new cancer cases and remains the most prevalent adult leukemia in western countries.

Myelodysplastic Syndrome (MDS)

Myelodysplastic syndromes are a group of clonal myeloid disorders with a relatively heterogeneous spectrum of presentation caused by poorly formed blood cells or ones which malfunction.

Non-Hodgkin Lymphomas (NHL)

Non-Hodgkin lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders which originates in B-lymphocytes, T-lymphocytes, or natural killer (NK) cells representing 4.2% of all new cancer cases.

Lung Cancer

Lung cancer represents 12.9% of all new cancer cases and is the main cause of cancer death in western countries. Only 18% of all lung cancer patients are alive 5 years after diagnosis.

Breast Cancer

Breast cancer represents 15.2% of all new cancer cases and is the most frequently diagnosed cancer globally and the leading cause of cancer-related death in women.

Pancreatic Cancer

Pancreas cancer represents 3.2% of all new cancer cases. Only 9.3% survive for more than 5 years. Pancreatic adenocarcinoma is the fourth most common cause of cancer-related death among U.S. men (after lung, prostate, and colorectal cancer) and women (after lung, breast, and colorectal cancer).